Technology | October 27, 2014

FDA Clears Self-Expanding Peripheral Stent System

The thin, flexible stent is indicated for the iliac arteries that supply blood to the pelvis and legs

Everflex stent, Covidien, ev3

Oct. 27, 2014 — The U.S Food and Drug Administration (FDA) cleared the EverFlex Self-Expanding Peripheral Stent System. The stent was developed by ev3, which is now a part of Covidien.

The thin, flexible stent is indicated for the iliac arteries that supply blood to the pelvis and legs. The stent is an implant made of a nickel-titanium alloy (nitinol) tubing and laser cut into a mesh shape. The stent is mounted in a long, thin, tube-like device called the delivery

The FDA said generally, patients who are not suitable candidates for balloon angioplasty are also not suitable candidates for stent placement. The EverFlex Self-Expanding Peripheral Stent System should also not be used in patients who:

  • Have known allergies to the metals in the stent.
  • Have a blockage that will not allow complete inflation of the angioplasty balloon or proper placement of the stent.
  • Cannot take medicines that thin the blood or prevent blood clots.
  •  

?For more information: www.accessdata.fda.gov

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init